LUIGI PORCARO

Dr. LUIGI PORCARO

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

9 July 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GAGianluigi Ardissino
Gianluigi Ardissino
VCValentina Capone
Valentina Capone
STSilvana Tedeschi
Silvana Tedeschi
LPLUIGI PORCARO
LUIGI PORCARO
MCMassimo Cugno
Massimo Cugno
Thrombotic microangiopathy (TMA) is a complication that may occur after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) and is conventionally called transplant-associated thrombotic microangiopathy (TA-TMA). Despite the many efforts made to understand the mechanisms of TA-TMA, its pathogenesis is largely unknown, its diagnosis is challenging and the case-fatality rate remains high. The hallmarks of TA-TMA, as for any TMA, are platelet consumption, hemolysis, and organ dysfunction, particularly the kidney, leading also to hypertension. However, coexisting complications, such as infections and/or immune-mediated injury and/or drug toxicity, together with the heterogeneity of diagnostic criteria, render the diagnosis difficult. During the last 10 years, evidence has been provided on the involvement of the complement system in the pathophysiology of TA-TMA, supported by functional, genetic, and therapeutic data. Complement dysregulation is believed to collaborate with other proinflammatory and procoagulant factors to cause endothelial injury and consequent microvascular thrombosis and tissue damage. However, data on complement activation in TA-TMA are not sufficient to support a systematic use of complement inhibition therapy in all patients. Thus, it seems reasonable to propose complement inhibition therapy only to those patients exhibiting a clear complement activation according to the available biomarkers. Several agents are now available to inhibit complement activity: two drugs have been successfully used in TA-TMA, particularly in pediatric cases (eculizumab and narsoplimab) and others are at different stages of development (ravulizumab, coversin, pegcetacoplan, crovalimab, avacopan, iptacopan, danicopan, BCX9930, and AMY-101).

2 February 2023 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
CCCarla Colombo
Carla Colombo
GRGrant A Ramm
Grant A Ramm
ALAnders Lindblad
Anders Lindblad
FCFabiola Corti
Fabiola Corti
LPLUIGI PORCARO
LUIGI PORCARO
GAGianfranco Alicandro
Gianfranco Alicandro

9 May 2020 in Proteomes
Verified
Journal Article
Open access
PDF file
FRFrancesca Raimondo
Francesca Raimondo
CCClizia Chinello
Clizia Chinello
LPLUIGI PORCARO
LUIGI PORCARO
FMFulvio Magni
Fulvio Magni
MPMarina Pitto
Marina Pitto
Renal tubular cells release urinary extracellular vesicles (uEV) that are considered a promising source of molecular markers for renal dysfunction and injury. We investigated uEV proteomes of patients with hereditary salt-losing tubulopathies (SLTs), focusing on those caused by Gitelman and Bartter (BS) syndromes, to provide potential markers for differential diagnosis. Second morning urine was collected from patients with genetically proven SLTs and uEV were isolated by the ultracentrifugation-based protocol. The uEV proteome was run through a diagonal bidimensional electrophoresis (16BAC/SDS-PAGE), to improve hydrophobic protein resolution. Sixteen differential spots from the proteome of two variants (BS2 and BS3) were analysed by nLC-ESI-MS/MS after in-gel tryptic digestion. A total of 167 protein species were identified from 7 BS2 spots and 9 BS3 spot. Most of these proteins were membrane-associated proteins, in particular transmembrane proteins, and were related to typical renal functions. The differential content of some uEV was then validated by immunoblotting. Our work suggests that uEV proteomics represents a promising strategy for the identification of differential SLT proteins. This could play a role in understanding the pathophysiological disease mechanisms and may support the recognition of different syndromes.

6 March 2023 in Blood
Verified
Journal Article
Closed access
PDF file
MCMassimo Cugno
Massimo Cugno
IMIlaria Mancini
Ilaria Mancini
Dario ConsonniDario Consonni
Dario Consonni
VZValentina De Zan
Valentina De Zan
GAGianluigi Ardissino
Gianluigi Ardissino
FPFlora Peyvandi
Flora Peyvandi
Massimo Cugno, Ilaria Mancini, Dario Consonni, Valentina De Zan, Gianluigi Ardissino, Samantha Griffini, Elena Grovetti, Luigi Porcaro, Barbara Ferrari, Andrea

20 November 2025 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
VRValeria Rimoldi
Valeria Rimoldi
GSGiulia Soldà
Giulia Soldà
ACAnita Capalbo
Anita Capalbo
ESElena Saba
Elena Saba
VGValentina Giannone
Valentina Giannone
LSLetizia Straniero
Letizia Straniero
Cystic Fibrosis (CF) results from CFTR gene mutations, including splicing defects such as the polymorphic TGnTm repeat, which disrupts exon-10 inclusion and contributes to CF monosymptomatic forms. While recent advances in CF treatment have led to targeted therapies for specific CFTR defects, most splicing variants remain without an effective treatment. Small molecules, like the plant cytokine kinetin, have shown promise in correcting splicing defects in other genetic diseases, offering potential for personalized CF therapies. This study evaluated the efficacy of kinetin and its analogue, RECTAS, in correcting CFTR exon-10 splicing defects caused by TGnTm repeats. Cell models and patient-derived cells were treated with both compounds to assess their ability to enhance exon-10 inclusion. The impact of these treatments on splicing correction and CFTR protein expression was analyzed using molecular and cellular assays. Both kinetin and RECTAS improved exon-10 inclusion, with RECTAS demonstrating superior efficacy, achieving up to a four-fold increase in patient-derived cells compared to kinetin. Additionally, RECTAS consistently rescued exon-10 splicing across various TG-T alleles and successfully restored CFTR protein expression, highlighting its potential as a more potent therapeutic option. These findings identify RECTAS as an effective modulator of CFTR splicing. Rather than stand-alone therapeutics, kinetin and its analogues may act as transcript amplifiers, thereby possibly enhancing the efficacy of existing CFTR modulators. This approach could broaden treatment options for splicing-related CFTR variants and other genetic disorders.